Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors

Lévesque, Linda E.; Brophy, James M.; Bin Zhang
May 2006
CMAJ: Canadian Medical Association Journal;5/23/2006, Vol. 174 Issue 11, Special Section p1
Academic Journal
Background: The timing of cardiovascular risks associated with the use of cyclooxygenase-2 (COX-2) inhibitors is unclear. Using data collected in a previous population-based cohort study of elderly people starting nonsteroidal anti-inflammatory drug (NSAID) therapy, we evaluated the temporal nature of the risk of a first myocardial infarction (MI) associated with the use of rofecoxib and celecoxib. Methods: We identified people 66 years of age or older without previous MI who were currently taking rofecoxib and celecoxib using Quebec's computerized health databases (January 1999 to June 2002). Data on use and MI outcome were analyzed using a time-matched, nested case--control approach with rate ratios, comparing current users and non-users of rofecoxib and celecoxib in the year preceding the index date, estimated using conditional logistic regression. Results: The risk of MI was highest following first-time use of rofecoxib (adjusted rate ratio [RR] 1.67, 95% confidence interval [CI] 1.21-2.30), with events occurring within a median of 9 (6-13) days after therapy was started. The risk increase for first-time use of celecoxib was not statistically significant (RR 1.29, 95% CI 0.90-1.83). Repeated exposure to rofecoxib was associated with a small but statistically non-significant delayed risk (RR 1.17, 95% CI 0.98-1.40), but no risk was seen with celecoxib (RR 0.97, 95% CI 0.82-1.14). Treatment duration was not associated with increasing risk for either agent. The risk remained elevated for the first 7 days after rofecoxib was discontinued (RR 1.23, 95% CI 1.05-1.44) but appeared to return to baseline between day 8 and 30 (RR 0.82, 95% CI 0.61-1.09). Interpretation: A small proportion of patients using rofecoxib for the first time had their first MI shortly after starting the drug. This risk did not increase with the length of treatment and returned to baseline shortly after treatment was discontinued. More research is needed to identify those most susceptible to cardiotoxicity mediated by COX-2 inhibitor therapy.


Related Articles

  • NSAIDs after a MI could be fatal.  // Reactions Weekly;12/3/2005, Issue 1080, p5 

    The article discusses research being done on the association of COX-2 inhibitors and other nonsteroidal anti-inflammatory agents (NSAID) with the risk of death after a myocardial infarction (MI). It references a study by G. H. Gislason et al published in the October 25, 2005 issue of the...

  • Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction. Kimmel, Stephen E.; Berlin, Jesse A.; Reilly, Muredach; Jaskowiak, Jane; Kishel, Lori; Chittams, Jesse; Strom, Brian L. // Annals of Internal Medicine;2/1/2005, Vol. 142 Issue 3, p157 

    Background: Studies have postulated that cyclooxygenase-2 (COX-2) selective inhibitors affect cardiovascular risk through various mechanisms. Some of these mechanisms could increase risk (for example, inhibition of prostacyclin production), and some could decrease risk (for example, inhibition...

  • Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Anti-Inflammatory Drugs among Myocardial Infarction Patients - A Nationwide Study. Olsen, Anne-Marie Schjerning; Fosbøl, Emil L.; Lindhardsen, Jesper; Andersson, Charlotte; Folke, Fredrik; Nielsen, Mia B.; Køber, Lars; Hansen, Peter R.; Torp-Pedersen, Christian; Gislason, Gunnar H. // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Background: Non steroidal anti-inflammatory drugs (NSAIDs) increase mortality and morbidity after myocardial infarction (MI). We examined cause-specific mortality and morbidity associated with NSAIDs in a nationwide cohort of MI patients. Methods and Results: By individual-level linkage of...

  • The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Brophy, J. M.; Lévesque, I. E.; Zhang, B. // Heart;Feb2007, Vol. 93 Issue 2, p189 

    Background: Cyclo-oxygenase-2 selective inhibitors have been associated with cardiovascular side effects, but previous studies have generally excluded people with previous myocardial infarction, thereby limiting our knowledge of their cardiotoxicity in this population. Objectives: To determine...

  • Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Motsko, Stephen P.; Rascati, Karen L.; Busti, Anthony J.; Wilson, James P.; Barner, Jamie C.; Lawson, Kenneth A.; Worchel, Jason // Drug Safety;2006, Vol. 29 Issue 7, p621 

    BACKGROUND AND OBJECTIVE: The search for NSAIDs with less gastrointestinal toxicity led to the introduction of the selective cyclo-oxygenase-2 (COX-2) inhibitors. However, following their introduction into the market, concerns have developed regarding their safety, particularly their...

  • Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Hippisley-Cox, Julia; Coupland, Carol // BMJ: British Medical Journal (International Edition);6/11/2005, Vol. 330 Issue 7504, p1366 

    Presents a study to determine the comparative risk of myocardial infarction in patients treated with cyclo-oxygenase-2 and other non-steroidal anti-inflammatory drugs (NSAIDs) in primary care during 2000 and 2004, the risks in patients with and without coronary heart disease, as well as the risk...

  • Increased risk of MI with COX-2 inhibitors among patients with history of MI.  // Formulary;May2007, Vol. 42 Issue 5, p285 

    The article reports on the study, which aims to assess the risk of cardiovascular side effects associated with cyclo-oxyenase-2 (COX-2) inhibitors in patients with a history of myocardial infarction (MI). About 122,079 patients were enrolled in the study and were given a nonsteroidal...

  • COX-2 chronology. Hawkey, C. J. // Gut;Nov2005, Vol. 54 Issue 11, p1509 

    The role of selective cyclooxygenase (COX)-2 inhibitors in medical practice has become controversial since evidence emerged that their use is associated with an increased risk of myocardial infarction. Selective COX-2 inhibitors were seen as successor to non-selective non-steroidal...

  • Cox-2 risk 'overblown'. Cressey, Daniel // Pulse;5/4/2006, Vol. 66 Issue 18, p8 

    The article reports on research headed by King's College London senior instructor Ernest Choy probing the contribution of non-steroidal anti-inflammatory drugs and cox-2 inhibitors to incidence of heart attack in Great Britain. The study shows that the medicine carries minimal risk coronary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics